Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | PRKDC | P78527 | 4/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16303010 | 0.92 | ALOX5 (0.66) | ALOX5PRKDCGGPS1PTGES2PIK3CD | |
| SCHEMBL4549418 | 0.88 | ALOX5 (0.52) | ALOX5PRKDCGGPS1MAOBMAOA | |
| SCHEMBL4549415 | 0.87 | ALOX5 (0.51) | ALOX5PRKDCGGPS1MAOBMAOA | |
| SCHEMBL25775061 | 0.86 | ALOX5 (0.50) | ALOX5PRKDCGGPS1MAOBMAOA | |
| SCHEMBL9917129 | 0.86 | ALOX5 (0.59) | ALOX5PRKDCGGPS1MAOBMAOA | |
| SCHEMBL25118635 | 0.86 | ALOX5 (0.59) | ALOX5PRKDCGGPS1PTGES2PIK3CD | |
| SCHEMBL17167456 | 0.86 | ALOX5 (0.59) | ALOX5PRKDCGGPS1PTGES2PIK3CD | |
| SCHEMBL4549416 | 0.86 | ALOX5 (0.53) | ALOX5PRKDCGGPS1MAOBMAOA | |
| SCHEMBL4549414 | 0.85 | ALOX5 (0.52) | ALOX5PRKDCGGPS1MAOBMAOA | |
| SCHEMBL6003274 | 0.85 | ALOX5 (0.58) | ALOX5PRKDCGGPS1PTGES2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170162790-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2017-06-08 | — | — | US | disclosed |
| US-9614160-B2 | Aromatic amine derivatives and organic electroluminescent elements using same | IDEMITSU KOSAN CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160064669-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9260390-B2 | Aromatic amine derivatives and organic electroluminescent elements using same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20120146014-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170162790-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | RER1, NR4A1, REL | ALOX5 1894/4885PRKDC 4598/4885GGPS1 4829/4885 |
| US-20120146014-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | PNMT, TYR, AOC2 | ALOX5 1407/4885PRKDC 4060/4885GGPS1 3849/4885 |
| US-20160064669-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | PNMT, TYR, AOC2 | ALOX5 1407/4885PRKDC 4060/4885GGPS1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.